qb3at953 News

News Archive

We Welcome Engine Biosciences

Engine Biosciences is a venture-backed technology company integrating experimental biology and data science to map and decipher complex biological networks for more effective and efficient drug discovery. Engine’s technologies culminate from several years of research by our scientific founders who include faculty members of MIT, Harvard, Mayo Clinic, and UCSD, and our leadership team is applying our previous successful company […]

Read more

We Welcome Scribe Biosciences

Scribe Biosciences is developing the next generation of high throughput single cell analysis tools for clinical and research applications. The company is based on Printed Droplet Microfluidics (PDM), a technology spun out of the Abate and Gartner labs at UCSF to enable the flexible and programmable handling of single cells with unsurpassed control. Scribe is currently being contracted by DARPA […]

Read more

We Welcome Mitokinin

Mitokinin is developing a novel class of kinase-targeted neo-substrates for the treatment of neurodegenerative and mitochondrial diseases.

Read more

We Welcome Prellis Biologics

  Prellis Biologics is developing technology to build transplantable human organs and tissues. Their aim is to address the organ shortage and provide human tissues to streamline the development of therapeutics. The first transplantable human tissues Prellis Biologics is working to develop are the insulin secreting units of the pancreas, Islets of Langerhans. A renewable, safe source of Islets of […]

Read more

New partnership with TetraScience

QB3@953 is happy to announce an exciting new partnership with TetraScience, the leading Internet of Things for science company. QB3@953’s goal is to be the most efficient and “lean” lab on the planet, and TetraScience’s ability to connect existing instruments and lab systems to a single online dashboard, will help us reach this goal. We are also working on new projects […]

Read more

These seven researchers are changing the face of biotech

These seven researchers are changing the face of biotech Read the complete article at BizJournals Three of the Magnificent 7 are women CEOs at QB3@953 which we want to highlight in our post. June 8, 2017, Bay Area Biotech From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening […]

Read more

New Core Equipment: GE WAVE 25

New Core Equipment: GE WAVE 25 The WAVE 25 bioreactor system will allow QB3@953 startups to reliably and repeatedly grow up to 25L of cells for protein production. The single use bags standardize production and eliminates the need for clean-rooms, all of which saves time and money. We are dedicated to helping our researchers get reliable data fast – and […]

Read more

Servier partners with QB3@953 to find and cultivate innovative startups

Servier is the second largest French pharmaceutical company with over 3,000 researchers focused on novel treatments for cardiovascular disease, oncology, diabetes, CNS, and Rheumatology. This partnership is a boon for researchers on both sides of the Atlantic, bringing together Servier’s decades of expertise and QB3@953’s innovative thinking and startup community. Servier will receive a “golden ticket,” which allows Servier to […]

Read more

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth

Laboratory Space Shortage Constrains Southside San Francisco Biotech Growth QB3@953, a biotech incubator, has been so successful that many of the startups housed there are searching for larger laboratories in Southside San Francisco. But their moves have been stymied by high rents and real estate prices, as well as a lack of space for midsize companies. The incubator, launched almost […]

Read more

Rich Yu talks about how incubator saving water during CA drought

Rich Yu talks about how incubator saving water during CA drought Richard Yu, Ph.D., scientific and operations director for the QB3@953 incubator in San Francisco, told GEN his facility is also heeding the need for water conservation. “I flagged a person for using cold running water to cool an eletrophoresis gel and begged them to use a recirculating water chiller, […]

Read more
Page 1 of 212

qb3at953 News

Upcoming Event

  • Tosoh Hour

    14:00-15:30
    12/14/2017
    1. HPLC Products 2. Business Development and Venture Investment Our newest sponsor Tosoh will be here on December 14th. Amongst Tosoh's interests is the Separations and Purification Division.  Their scientist, Philip Hoang, will be here and would be happy to meet with you to discuss your purification challenges. He will be joined by Toshifumi Mogami and Kenichi Haga from Tosoh's Venture and Business Development Units. Tosoh is most interested in companies working in diagnostics and research tools.  Please contact Linda Eng if you'd like to meet with them. Toshifumi Mogami, PhD, is Vice President of Business Development & Venture Investment from Tosoh USA, Inc., the venture capital arm of Tosoh Corporation. Toshifumi has a background in biophysics and bioengineering. Kenichi Haga is Senior Vice President of Business Development and Venture Investment from Tosoh USA, Inc. and his background is in organic chemistry. Philip Hoang is an Account Manager of HPLC Columns for the West Coast. He is responsible for sales and support of HPLC/UHPLC columns in California, Oregon and Washington state. Philip received his bachelor’s degree in biology from California State University, Long Beach. He has five years of technical experience in the HPLC and UHPLC field, where his work focused on the analysis of mAbs and ADCs.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter